Jefferies Financial Group Inc. Invests $1.10 Million in Glaukos Corporation $GKOS

Jefferies Financial Group Inc. acquired a new stake in shares of Glaukos Corporation (NYSE:GKOS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 7,856 shares of the medical instruments supplier’s stock, valued at approximately $1,098,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Allworth Financial LP bought a new stake in Glaukos during the 2nd quarter worth approximately $28,000. Los Angeles Capital Management LLC bought a new position in Glaukos in the fourth quarter valued at approximately $28,000. Larson Financial Group LLC boosted its holdings in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 226 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 215 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Price Performance

Shares of GKOS opened at $179.95 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $191.62. The stock has a market capitalization of $10.61 billion, a P/E ratio of -55.37 and a beta of 0.78. The company has a 50 day moving average of $162.64 and a 200-day moving average of $134.10.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. As a group, equities research analysts forecast that Glaukos Corporation will post -0.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GKOS. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Truist Financial increased their target price on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Wells Fargo & Company lifted their price target on Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Finally, UBS Group started coverage on Glaukos in a report on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 price target on the stock. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $178.08.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 60,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares in the company, valued at $13,046,967.12. This trade represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 113,025 shares of company stock valued at $19,600,006 over the last quarter. 5.90% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.